CD30-targeting immunoconjugates and bystander effects.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

1. Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.Investigational new drugs · 2021
   Trial
2. Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers.Journal for immunotherapy of cancer · 2025
   Article
3. Antibody-Based Therapies for Peripheral T-Cell Lymphoma.Cancers · 2024
   Review
4. T cell receptor-directed antibody-drug conjugates for the treatment of T cell-derived cancers.Molecular therapy. Oncology · 2024
   Article
5. Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity.Frontiers in immunology · 2023
   Article
6. Bystander effect of antibody-drug conjugates: fact or fiction?Current oncology reports · 2022
   Review
7. Atorvastatin Inhibits the HIF1α-PPAR Axis, Which Is Essential for Maintaining the Function of Human Induced Pluripotent Stem Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
   Article
8. Fate of Antibody-Drug Conjugates in Cancer Cells.Journal of experimental & clinical cancer research : CR · 2018
   Review
9. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?British journal of cancer · 2017
   Review
10. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.Journal of pharmacokinetics and pharmacodynamics · 2016
    Article
11. Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity.mAbs
    Article

Corrections and comments

• Comment on
  The development of immunoconjugates for targeted cancer therapy.2014

Authors and funding

4 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as